Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

30.27 +0.18 (+0.58%)

Streaming Delayed Price Updated: 12:00 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s...

Via The Motley Fool

Topics Regulatory Compliance

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Via The Motley Fool

Topics Regulatory Compliance

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

Why Edgewise Therapeutics Stock Crushed the Market on Monday ↗

February 09, 2026

The company will publish very encouraging results from a clinical trial soon, one pundit believes.

Via The Motley Fool

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Why Edgewise Therapeutics Stock Rocked the Market Today ↗

December 24, 2025

The company just might have a winner on its hands with a pipeline heart disease treatment.

Via The Motley Fool

Let's take a look at the stocks that are in motion in today's session. ↗

December 24, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗

December 24, 2025

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said.

Via Stocktwits

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Edgewise Therapeutics Inc (NASDAQ:EWTX) Q2 2025 Earnings: EPS Beat Sparks 5% Pre-Market Rally ↗

August 07, 2025

Edgewise Therapeutics (EWTX) reports Q2 2025 EPS beat at -$0.34 vs. -$0.42 estimates, sparking a 5% pre-market rally. Clinical progress in muscle disease treatments drives optimism.

Via Chartmill

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 30, 2025

Via Benzinga

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall ↗

June 26, 2025

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.

Via Benzinga

Top movers in Friday's after hours session ↗

May 23, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 12, 2025

Via Benzinga

Why Edgewise Therapeutics Stock Popped This Week ↗

May 02, 2025

Via The Motley Fool

Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

April 21, 2025

Via Benzinga

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 ↗

April 10, 2025

Via Benzinga

Top movers in Wednesday's session ↗

April 02, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

These stocks are moving in today's session ↗

April 02, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 02, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

April 02, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.